Skip to main content
SpringerLink
Log in

Molecular dynamics simulated validation of anti-cancerous alkaloids as Topo IIβ inhibitors screened by QSAR, pharmacophore and molecular docking approaches

  • Original Research
  • Published:
Medicinal Chemistry Research Aims and scope Submit manuscript

Abstract

Looking to the recent roles of topoisomerases in various types of cancers, in the present paper, a quantitative structure–activity relationship model, based on genetic function approximation (GFA) method, was developed using 41 olivacine derivatives as inhibitors of topoisomerase IIβ (Topo IIβ). The best predictive GFA model explained the biological activity of the training and test sets with correlation coefficient values (r 2) of 0.747 and 0.549, respectively, and a significant cross-validated correlation coefficient (q 2) of 0.525. The model suggested positive correlation between activity and descriptors, namely partition coefficient (ALogP), electrostatic energy, number of hydrogen bond acceptors and number of rotatable bonds, while those of negative correlations with Jurs RPCG, Jurs TASA and PHI. Furthermore, a common feature-based pharmacophore model for these inhibitors was also developed which comprised of five features, namely one H-bond acceptor, two ring aromatic, one positive ionizable and one hydrophobic group. Screening of a large database for natural compounds, using both these developed models, led to identification of the pyrrole derivative, namely 1-(2-(dimethylamino)ethyl)-3-hydroxy-4-(4-methoxy-2-methylbenzoyl)-5-(3,4,5-trimethoxyphenyl)-1H-pyrrol-2(5H)-one (compound ID: STOCK1N-31995) with a predicted IC50 value of 0.3 × 10−6 µM as most potent inhibitor of Topo IIβ. The result of virtual screening was further validated using molecular dynamics (MD) simulation analysis. Thus, a 15 ns MD simulation analysis revealed high stability and effective binding of 1-(2-(dimethylamino)ethyl)-3-hydroxy-4-(4-methoxy-2-methylbenzoyl)-5-(3,4,5-trimethoxyphenyl)-1H-pyrrol-2(5H)-one within the active site of Topo IIβ.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  • Ahirwar S, Shrivastava A, Pathak AK (2014) 2D QSAR study of novel quinoline derivatives as potent antitubercular agents. J Comput Meth Mol Des 4:6–13

    Google Scholar 

  • Asgaonkar KD, Mote GD, Chitre TS (2014) QSAR and Molecular docking studies of oxadiazole-ligated pyrrole derivatives as Enoyl-ACP (CoA) reductase inhibitors. Sci Pharm 82:71–85

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Auradee P, Pungpo P, Kamsri P, Kasamsri D, Srisupan A, Saparpakorn P, Hannongbua S, Wolschann P, Prueksaaroon S, Pongprom N (2013) Molecular dynamics simulations of azanaphthoquinone annelated pyrrole derivatives as anticancer agent in DNA duplex. Comput Biochem Biophy 4:555–562

    Google Scholar 

  • Austin CA, Sng JH, Patel S, Fisher LM (1993) Novel HeLa Topo II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases. Biochem Biophys Acta 1172:283–291

    CAS  PubMed  Google Scholar 

  • Awasthi M, Singh S, Pandey VP, Dwivedi UN (2015) Molecular docking and 3D-QSAR based virtual screening of flavonoids as potential aromatase inhibitors against estrogen-dependent breast cancer. J Biomol Struct Dyn 33:804–819

    Article  CAS  PubMed  Google Scholar 

  • Braybrooke J, Ranson M, Manegold C (2003) Phase II study of mesylate (DX-8951F) as first line therapy for advanced non-small cell lung cancer. Lung Cancer 41:215–219

    Article  CAS  PubMed  Google Scholar 

  • Burden DA, Osheroff N (1998) Mechanism of action of eukaryotic Topo II and drugs targeted to the enzyme. Biochem Biophys Acta 1400:139–154

    CAS  PubMed  Google Scholar 

  • Champoux JJ (2001) DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70:369–413

    Article  CAS  PubMed  Google Scholar 

  • ChandraSekhar KVG, Vyas DRK, Nagesh HN, Rao VS (2012) Pharmacophore hypotheses for atypical antipsychotics. Bull Korean Chem Soc 33:2930–2936

    Article  Google Scholar 

  • Chhatriwala H, Jafri N, Salgia R (2006) A review of Topo I inhibition in lung cancer. Cancer Biol Ther 5:1600–1607

    Article  CAS  PubMed  Google Scholar 

  • Dayam R, Laith Q, Al-Mawsawi ZZ, Myriam W, Zeger D, Nouri N (2008) Quinolone 3-carboxylic acid pharmacophore: design of second generation HIV-1 integrase inhibitors. J Med Chem 51:1136–1144

    Article  CAS  PubMed  Google Scholar 

  • Forte B, Malgesini B, Piutti C, Quartieri F, Scolaro A, Papeo G (2009) A submarine journey: the pyrrole-imidazole alkaloids. Mar Drugs 7:705–753

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Frimayanti N, Yam ML, Lee HB, Othman R, Zain SM, Rahman NA (2011) Validation of quantitative structure-activity relationship (QSAR) model for photosensitizer activity prediction. Int J Mol Sci 12:8626–8644

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Golbraikh A, Tropsha A (2002) Beware of q2. J Mol Graph Model 20:269–276

    Article  CAS  PubMed  Google Scholar 

  • Guillonneau C, Pierre A, Charton Y, Guilbaud N, Kraus-Berthier L, Le once S, Michel A, Bisagni E, Atassi G (1999) Synthesis of 9-O-substituted derivatives of 9-hydroxy-5, 6-dimethyl-6hpyrido [4, 3-b] carbazole-1-carboxylic acid (2-(Dimethylamino) ethyl) amide and their 10- and 11-methyl analogues with improved antitumor activity. J Med Chem 42:2191–2203

    Article  CAS  PubMed  Google Scholar 

  • Hansch C, Leo A (1995) In exploring QSAR: fundamentals and applications in chemistry and biology. American Chemical Society, Washington D.C

    Google Scholar 

  • Idhayadhulla A, Kumar SR, Nasser AJA, Manilal A (2011) Synthesis of some new pyrrole derivatives and their antimicrobial activity. Der Pharma Chemica 4:210–218

    Google Scholar 

  • Idhayadhulla A, Kumar SR, Nasser AJA, Manilal A (2013) Synthesis of some new pyrrole and pyridine derivatives and their antimicrobial, anticancer activities. Int J Biol Chem 7:15–26

    Article  CAS  Google Scholar 

  • Jarvinen TA, Liu ET (2003) HER-2/neu and Topo II alpha in breast cancer. Breast Cancer Res Treat 78:299–311

    Article  PubMed  Google Scholar 

  • Jenkins JR, Ayton P, Jones T, Davies SL, Simmons DL, Harris AL, Sheer D, Hickson ID (1992) Isolation of cDNA clones encoding the beta isozyme of human DNA Topo II and localization of the gene to chromosome 3p24. Nucleic Acids Res 20:5587–5592

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Kellner U, Sehestedb M, Jensenb PB, Gieselerc F, Rudolphd P (2002) Culprit and victim-DNA topoisomerase II. Lancet Oncol 3:235–243

    Article  CAS  PubMed  Google Scholar 

  • Khaled KF, Abdel-Shafi NS (2011) Quantitative structure and activity relationship modeling study of corrosion inhibitors: genetic function approximation and molecular dynamics simulation methods. Int J Electrochem Sci 6:4077–4094

    CAS  Google Scholar 

  • Konkimalla VB, Efferth T (2010) Inhibition of epidermal growth factor receptor over-expressing cancer cells by the aphorphine-type isoquinoline alkaloid, dicentrine. Biochem Pharmacol 79:1092–1099

    Article  CAS  PubMed  Google Scholar 

  • La RG, Bai R, Coluccia A, Famiglini V, Pelliccia S, Passacantilli S, Mazzoccoli C, Ruggieri V, Sisinni L, Bolognesi A, Rensen WM, Miele A, Nalli M, Alfonsi R, Di Marcotullio L, Gulino A, Brancale A, Novellino E, Dondio G, Vultaggio S, Varasi M, Mercurio C, Hamel E, Lavia P, Silvestri R (2014) New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer. J Med Chem 15:6531–6552

    Google Scholar 

  • Le Mee S, Pierre A, Markovits J, Atassi G, Jacquemin-Sablon A, Saucier JM (1998) S16020-2, a new highly cytotoxic antitumor olivacine derivative: DNA interaction and DNA topoisomerase II inhibition. Mol Pharmacol 53:213–220

    PubMed  Google Scholar 

  • Leon P, Garbay-Jaureguiberry C, Barsi MC, Le Pecq JB, Roques BP (1987) Modulation of the antitumor activity by methyl substitutions in the series of 7H-pyridocarbazole monomers and dimers. J Med Chem 30:2074–2080

    Article  CAS  PubMed  Google Scholar 

  • Liu LF (1994) DNA topoisomerases: biochemistry and molecular biology. Academic Press, New York

    Google Scholar 

  • Liu Y, Gao F, Jiang H, Niu L, Bi Y, Young CY, Yuan H, Lou H (2013) Induction of DNA damage and ATF3 by retigeric acid B, a novel Topo II inhibitor, promotes apoptosis in prostate cancer cells. Cancer Lett 337:66–76

    Article  CAS  PubMed  Google Scholar 

  • Martin MT, Harten P, Young DM, Muratov EN, Golbraikh A, Zhu H, Tropsha A (2012) Does rational selection of training and test sets improve the outcome of QSAR modeling? J Chem Inf Model 52:2570–2578

    Article  CAS  PubMed  Google Scholar 

  • More VD, Choudhari PB, Dhavale RP, Jadhav SD, Bhatia MS (2012) 3D QSAR study on alpha keto amide derivatives as gp120-CD4 inhibitors. Int J Pharm Sci Drug Res 4:19–24

    CAS  Google Scholar 

  • Mosher CW, Crews OP, Action EM, Goodman LJ (1966) Preparation and antitumor activity of olivacine and some new analogs. Med Chem 9:237–241

    Article  CAS  Google Scholar 

  • Munster PN, Daud AI (2011) Preclinical and clinical activity of the Topo I inhibitor, karenitecin, in melanoma. Expert Opin Investig Drugs 20:1565–1574

    Article  CAS  PubMed  Google Scholar 

  • Ohashi M, Oki T (1996) Ellipticine and related anticancer agents. Expert Opin Ther Pat 6:1285–1294

    Article  CAS  Google Scholar 

  • Ohashi M, Sugikawa E, Nakanishi N (1995) Inhibition of P53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism. Jpn J Cancer Res 86:819–827

    Article  CAS  PubMed  Google Scholar 

  • Patel A, Shah S, Panchal I (2014) Chemo resistance: a major hurdle of cancer therapeutics. Int J Pharma Bio Sci 3:256–267

    CAS  Google Scholar 

  • Pelaprat D, Delbarre A, Leguen I, Roques BP (1980) DNA intercalating compounds as potential antitumor agents. 2. Preparation and properties of 7H-pyridocarbazole dimers. J Med Chem 23:1336–1343

    Article  CAS  PubMed  Google Scholar 

  • Prescott TA, Sadler IH, Kiapranis R, Maciver SK (2007) Lunacridine from Lunasia amara is a DNA intercalating topoisomerase II inhibitor. J Ethnopharmacol 109:289–294

    Article  CAS  PubMed  Google Scholar 

  • Rogers D, Hopfinger AJJ (1994) Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. Chem Inf Comput Sci 34:854–866

    Article  CAS  Google Scholar 

  • Sakkiah S, Thangapandian S, John S, Lee KW (2011) Pharmacophore based virtual screening, molecular docking studies to design potent heat shock protein 90 inhibitors. Eur J Med Chem 46:2937–2947

    Article  CAS  PubMed  Google Scholar 

  • Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non small cell lung cancer. N Engl J Med 346:92–98

    Article  CAS  PubMed  Google Scholar 

  • Schmutz J, Hunzicker F (1958) Alkaloids of aspidosperma olivaceum. Acta Helv 30:341–347

    Google Scholar 

  • Schuttelkopf AW, van Aalten DM (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60:1355–1363

    Article  PubMed  Google Scholar 

  • Singh M, Singh SK, Chhabria MT (2012) A novel QSAR model for evaluating and predicting the inhibition activity of H1-receptor antagonists: a series of thienopyrimidine derivatives. J Drug Deliv Ther 2:6–15

    CAS  Google Scholar 

  • Tewey KM, Chen GL, Nelson EM, Liu LF (1984) Interactive antitumor drug interferes with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259:9182–9187

    CAS  PubMed  Google Scholar 

  • Thakur DS (2011) Topoisomerase II inhibitors in cancer treatment. Int J Pharm Sci Nanotechnol 3:1173–1181

    CAS  Google Scholar 

  • Tylinska B, Jasztold-Howorko R, Mastalarz H, Klopotowska D, Filip B, Wietrzyk J (2010) Synthesis and structure-activity relationship analysis of new olivacine derivatives. Acta Poloniae Pharm-Drug Res 67:495–502

    CAS  Google Scholar 

  • Vassetzky YS, Alghisi GC, Gasser SM (1995) DNA topoisomerase II mutations and resistance to anti-tumor drugs. Bioessays 17:767–774

    Article  CAS  PubMed  Google Scholar 

  • Veerasamy R, Rajak H, Jain A, Sivadasan S, Varghese CP, Agrawal RK (2011) Validation of QSAR models- strategies and importance. Int J Drug Des Discov 2:511–519

    CAS  Google Scholar 

  • Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 6:430–440

    Article  Google Scholar 

  • Yang SY (2010) Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov Today 15:440–450

    CAS  Google Scholar 

  • Zhang SX, Feng J, Kuo SC, Brossi A, Hamel E, Tropsha A, Lee KH (2000) Three-dimensional quantitative structure-activity relationship study of the colchicine binding site ligands using comparative molecular field analysis. J Med Chem 43:167–176

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Financial support from Department of Science and Technology (DST), Government of India, New Delhi in the form of DST-INSPIRE-SRF to SS is gratefully acknowledged. Financial supports from Department of Biotechnology, Government of India, New Delhi under BIF, DST under PURSE programme and Department of Higher Education, Government of Uttar Pradesh under Center of Excellence programme for infrastructural facilities are also gratefully acknowledged.

Conflict of interest

There is no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Biochemistry, Bioinformatics Infrastructure Facility, Centre of Excellence in Bioinformatics, University of Lucknow, Lucknow, 226007, Uttar Pradesh, India

    Swati Singh, Manika Awasthi, Veda P. Pandey & Upendra N. Dwivedi

  2. Amity Institute of Biotechnology, Amity University Lucknow, Lucknow, 226028, Uttar Pradesh, India

    Swati Singh & Brijesh Pandey

Authors
  1. Swati Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manika Awasthi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Veda P. Pandey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Brijesh Pandey
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Upendra N. Dwivedi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Upendra N. Dwivedi.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 68 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singh, S., Awasthi, M., Pandey, V.P. et al. Molecular dynamics simulated validation of anti-cancerous alkaloids as Topo IIβ inhibitors screened by QSAR, pharmacophore and molecular docking approaches. Med Chem Res 24, 2972–2985 (2015). https://doi.org/10.1007/s00044-015-1351-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00044-015-1351-7

Keywords

Search

Navigation